WASHINGTON, D. C. - Jami'ai sun bayyana gangamin da aka fara ranar Litinin a matsayin wani ci gaba na kokarin da aka kwashe shekaru ana yi na dakile yawaitar cutar wadda sauro ke yadawa a nahiyar, wadda kuma ke haddasa kashi 95% na mace-macen zazzabin cizon sauro a duniya.
“Alurar rigakafin za ta ceci rayuka. Za ta taimaka sosai ga iyalai da tsarin kiwon lafiyar kasar, "in ji Aurelia Nguyen, babban jami'in shirye-shirye na kungiyar Gavi vaccines alliance, wanda ke taimakawa Kamaru wajen samun nasarar rigakafin.
Kasar da ke yankin Afirka ta tsakiya na fatan yi wa yara kimanin 250,000 allurar rigakafin a wannan shekara da kuma shekara mai zuwa. Gavi ya ce kungiyar ta na aiki tare da wasu kasashen Afirka 20 don taimaka musu wajen samun rigakafin, kuma kasashen za su yi wa yara sama da miliyan 6 riga kafin nan da shekarar 2025.
A nahiyar Afirka akwai kimanin mutane miliyan 250 da ke kamuwa da cututuka masu alaka da cizon sauro a kowace shekara, ciki har da mutuwar 600,000, galibi a cikin yara kanana.
Kasar Kamaru za ta yi amfani da ta farko daga cikin allurar rigakafin zazzabin cizon sauro guda biyu da aka amince da su kwanan nan, da aka fi sani da Mosquirix. Hukumar Lafiya ta Duniya ta amince da rigakafin shekaru biyu da suka gabata, tare da bayyana cewa duk da yake ba'a hakikance sahihancinta ba, amfani da ita zai rage munanan cututtuka da kwantar da mutane a asibitoci.
Allurar rigakafin da GlaxoSmithKline ya samar ta na da tasiri kusan kashi 30% kacal, tana buƙatar allurai huɗu, amma kuma sai kariyar ta fara dusashewa bayan wasu watanni. An gwada maganin a Afirka kuma ana amfani da shi a shirye-shiryen gwaji a kasashe uku.
Dandalin Mu Tattauna